

**GOVERNMENT OF PAKISTAN**  
**THE PATENT OFFICE**  
2nd Floor, Kandawala Building,  
M.A. Jinnah Road,  
Karachi

No.2/2/2003-F.Sec.

Dated: 02-5-2008

To,

The Manager,  
Printing Corporation of Pakistan Press,  
University Road,  
Karachi

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE  
WEEKENDING 05-4-2008 TO BE PUBLISHED 03-5-2008 IN THE  
GAZETTE OF PAKISTAN PART-V.**

A manuscript copy of the weekly notification regarding application filed application accepted and scaling fee due etc., is forwarded herewith to be published in the next issue of the Gazette of Pakistan Part-V without fail.

**(Mrs. Yasmeen Abbasi)**  
Controller of Patents  
Ph: 9215488

ENCL:

## NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

349/2008	<b><u>31-3-2008</u></b> Neurocrine biosciences, Inc. USA (Priority 6-4-07 USA)	“Gonadotropin-releasing hormone receptor antagonists and methods relating thereof”
350/2008	Nestec. S.A., Switzerland (Priority 03-4-07 France)	“Process and device for producing a chilled dessert item containing a crunchy composition arranged in superimposed layers its mass”
351/2008	Bayer CropSCience Ag, Germany (Priority 23-4-07 Japan)	“Insecticidal aryl pyrrolidines”
352/2008	Bayer CropSCience Ag, Germany (Priority 10-4-07 Japan)	“Insecticidal aryl isoxazoline derivatives”
353/2008	Bayer Consumer Care Ag, Switzerland (Priority 17-4-07 Japan)	“Ginsenosides and extracts containing them combined with dexpanthenol”
354/2008	Bayer CropSCience Ag, Germany (Priority 17-4-07 Japan)	“Insecticidal derivatives of substituted aminoheterocycles”
355/2008	Vifor (International) AG, Switzerland (Priority 29-3-07 EP)	“Water-soluble iron-carbohydrate derivative complexes, the preparation thereof, and medicaments comprising them”
356/2008	<b><u>01-4-2008</u></b> 1. Amgen Fremont Inc., 2. Pfizer Inc. USA (Priority 02-4-07 USA)	“Anti-Ige antibodies”
357/2008	SmithKline Beecham Corporation, USA (Priority 02-9-04 USA)	“5, 6, 7, 8, -tetrahydro-8-quinolineamine imidazopyridinyl compounds for use in the treatment of HIV infection”

358/2008	Institute for One World Health, USA (Priority 02-4-07 US)	“CFTR inhibitor compounds and uses thereof”
	<b><u>02-4-2008</u></b>	
359/2008	Syngenta Participations Ag, Switzerland (Priority 04-4-07 Europe)	“Method of improving the growth of a plant”
360/2008	Saudi Basic Industries Corporation, Saudi Arabia (Priority 4-4-07 Europe)	“Combined reforming process for methanol production”
361/2008	AstraZeneca UK Limited, United Kingdom (Priority 31-5 96 GB) <b>Divisional</b>	“A sustained release formulation comprising a gelling agent and a pharmaceutically acceptable salt of 11-[4-[2-(2-hydroxyethoxy) ethyl]-1-piperazinyl] dibenzo-[b, f] [1, 4] thiazepine”
	<b><u>03-4-2008</u></b>	
362/2008	Neurocrine BioSciences, Inc., USA (Priority 6-4-07 USA)	“Gonadotropin-releasing hormone receptor antagonists and methods relating thereto”
363/2008	TransTech Pharma, Inc. USA (Priority 5-4-07 USA)	“Crystalline forms of [3-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy]-propyl]-diethyl-amine”
364/2008	AstraZeneca AB, Sweden (Priority 05-4-07 USA)	“New compounds and their uses 707”
365/2008	AstraZeneca AB, Sweden (Priority 24-12-02 Europe) <b>Divisional</b>	Intermediate useful in the preparation of quinoxaline compound”
366/2008	Farkhanda Ghafoor National Health Research Complex, Lahore (PAKISTAN)	“Elisa kit for microalbuminuria”
367/2008	Wyeth, USA (Priority 05-4-07 USA)	“Wortmannin-rapalog conjugate and uses thereof”

	<b><u>04-4-2008</u></b>	
368/2008	Aksnes Aviation AS Norway (Priority 12-4-07 Norway)	“A method for voice-control of a radio transmitter”
369/2008	Sanofi-Aventis France (Priority 19-4-07 France)	“Use of 4-cyclopropylmethoxy-n-(3, 5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy) pyridine-2-carboxamide in the treatment of motor disorders related to parkinson’s disease”
370/2008	Sanofi-Aventis France (Priority 05-4-07 Europe)	“5-oxoisoxazoles as inhibitors of lipases and phospholipases”
371/2008	Sanofi-Aventis France (Priority 05-4-07 Europe)	“Imidazolidinecarboxamide derivatives as inhibitors of lipases and phospholipases”
	<b><u>05-4-2008</u></b>	
372/2008	GEOX S. p. A., Italy, (Priority 17-4-07 Italy)	“Shoe with combined device for vapor permeation and forced air circulation”
373/2008	Vestergaard Frandsen SA. Switzerland (Priority 10-4-07 PCT/DK)	“Process for insecticidal impregnation of a fabric or netting or other kind of non-living material”
374/2008	Merck & Co., Inc. USA (Priority 11-4-07 USA)	“Substituted furo[2, 3-B] pyridine derivatives as cannabinoid-1 receptor modulators”

## APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

770/1999	Bayer Aktiengesellschaft, Germany.	“Microcapsule composition of a polyisocyanate “  (A01N 43/72)	139498
----------	--	---	--------

A) a particulate disperse phase of a) a reaction product of -at least one diamine, polyamine, dialcohol, polyalcohol and/or aminoalcohol with -an isocyanate mixture characterized in the description, if appropriate as a mixture with toluylene diisocyanate, b) at least one agrochemicallyactive compound of a particular group of substances and, c) if appropriate, additives, and B) a liquid aqueous phase, and their use for applying the active compound which they comprise.

617/2000	F. Hoffmann-La Roche AG. Switzerland.	“A conjugate comprising erythropoirtin compound”  (INT: CL, A61K 47/48)	139499
----------	---	--	--------

The present invention refers to conjugates of erythropoietin with poly(ethylene glycol) comprise an erythropoietin glycoprotein having at least one free amino group and having the in vivo biological activity of causing bone marrow cells to increase production of reticulocytes and red

blood cells and selected from the group consisting of human erythropoietin and analogs thereof which have sequence of human erythropoietin modified by the addition of from 1 to 6 glycosylation sites or a rearrangement of at least one glycosylation site; said glycoprotein being covalently linked to "n" poly(ethylene glycol) groups of the formula  $-\text{CO}-(\text{CH}_2)_x(\text{OCH}_2)_m-\text{OR}$  with the carbonyl of each polyethylene glycol) group forming an amide bond with one of said amino groups; wherein R is lower alkyl; x is 2 or 3; m is about 450 to about 900; n is from 1 to 3; and n and m are chosen so that the molecular weight of the conjugate minus the erythropoietin glycoprotein is from 20 kilodaltons to 100 kilodaltons.


671/2000 Merck Patent GmbH. Germany.

“Substituted piperazine-carbonyl-indole compound”

(C07D 209/04)

139500

Compound of the formula I



in which R<sub>1</sub> and R<sub>3</sub> have the meanings indicated in Claim 1, are potent 5-(H)T<sub>2</sub>A antagonists and are suitable for the treatment of psychoses, schizophrenia, depression, neurological disorders, memory disorders, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, eating disorders such as bulimia, nervous anorexia, premenstrual syndrome and/or for positively affecting compulsive behaviour (obsessive-compulsive disorder, OCD).

1081/2004 Insung Powdertech Co., Ltd. Korea.

“Synthetic fiber containing powders with the shape of hollow sphere”

(D01 F1/02)

139501

Disclosed is a synthetic fiber, including hollow sphere-shaped particles each formed of any one selected from among an inorganic material, an organic material, or combinations thereof, which is advantageous in terms of a low specific gravity, thereby effectively solving conventional wearing problems.

412/2005 Novibra GmbH.  
Germany.

“Coupling between thread carrier and upper spindle part of a spinning or twisting spindle”

(B65H 54/54)

139502

Described is a coupling for the positive locking rotational taking along of a tube-shaped thread carrier by means of a rotatable upper spindle part of a spinning or twisting spindle. The thread carrier comprises longitudinal ribs which project radially inwards and serve simultaneously to centre the thread carrier. Longitudinal grooves are applied to the upper spindle part, which grooves are assigned to the longitudinal ribs. The longitudinal grooves are shorter at their end facing away from the spindle tip than the longitudinal ribs, and the groove base passes at this end into a groove-free centring surface, on which the longitudinal ribs lie with a matched sliding fit. Thus the functions of centring and positive locking rotational taking along of the thread carrier are separated.

760/2007 F. Hoffmann-La  
Roche AG.  
Switzerland.

“A process for the preparation of a conjugate comprising erythropoietin compound”

(INT: CL ,A61K 47/48)

139503

The present invention refers to process of preparation of a conjugates of erythropoietin with poly(ethyleneglycol) comprising an erythropoietin glycoprotein having at least one free amino group and having the in vivo biological activity of causing bone marrow cells to increase production of reticulocytes and red blood cells and selected from the group consisting of human erythropoietin and analogs thereof which have

sequence of human erythropoietin modified by the addition of from 1 to 6 glycosylation sites or a rearrangement of at least one glycosylation site; said glycoprotein being covalently linked to "n" poly(ethyleneglycol) groups of the formula-CO-(CH<sub>2</sub>)<sub>x</sub> (OCH<sub>2</sub>CH<sub>2</sub>)<sub>m</sub>-OR with the carbonyl of each poly (ethylene glycol) group forming an amide bond with one of said amino groups; wherein R is lower alkyl; x is 2 or 3; m is about 450 to about 900; n is from 1 to 3; and n and m are chosen so that the molecular weight of the conjugate minus the erythropoietin glycoprotein is from 20 kilodaltons to 100 kilodaltons.

XXXXXXXXXXXXXXXXXXXX

**(Mrs. Yasmeen Abbasi)**  
Controller of Patents  
Ph: 9215488